Conatus Pharmaceuticals Inc.
4365 Executive Drive
118 articles with Conatus Pharmaceuticals Inc.
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
Conatus Pharmaceuticals Inc. announced that Institutional Shareholder Services Inc. and Glass Lewis, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020.
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
Conatus Pharmaceuticals Inc. convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc.
Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.
Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update
Conatus Pharmaceuticals Inc. announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.
The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction.
Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member.
Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results
Conatus Pharmaceuticals Inc. announced financial results for the quarter and nine months ended September 30, 2019..
Conatus indicated that it is considering a sale of the company as part of an exploration of strategic alternatives. It is already implementing a restructuring plan that will cut 40% of staff and suspend development of its inflammasome compound CTS-2090.
In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
Conatus Pharmaceuticals Inc. announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one addressing preclinical results with the company’s pan-caspase inhibitor, IDN-7314 – have been accepted for oral presentations; and one abstract addressing preclinical results with emricasan has been accepted for a poster presentation at The Liver Meeting®
Conatus Pharma Appoints Keith W. Marshall As Executive Vice President, Chief Operating Officer And Chief Financial Officer
Conatus Pharma Announces Completion Of Enrollment In ENCORE-NF Phase IIb Clinical Trial Of Emricasan In Patients With NASH Fibrosis
Conatus Pharma Reports Second Quarter 2017 Financial Results And Program Updates
Conatus Pharma To Report Second Quarter 2017 Financial Results
Conatus Pharma Announces Effectiveness Of Exclusive License For Global Development And Commercialization Of Emricasan With Receipt Of $7 Million Payment
FDA Grants Conatus Pharma Orphan Drug Designation For IDN-7314 For The Treatment Of PSC
Conatus Pharma Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Conatus Pharma Announces Proposed Public Offering Of Common Stock